Lai Yu Tsun, Thaciane Alkmim Bibo, Fernando Luiz Affonso Fonseca, Glaucia Luciano da Veiga, Ana Carolina Macedo Gaiatto, Nicolle de Godoy Moreira E Costa, Joyce Regina Raimundo, Matheus Moreira Perez, Thaís Gascón, Fulvio Alexandre Scorza, Carla Alessandra Scorza, Helena Nader, Manoel João Batista Castello Girão, Beatriz da Costa Aguiar Alves, Edimar Cristiano Pereira
{"title":"Quantification of Vitamin D at Different Levels of Clinical Worsening of COVID-19.","authors":"Lai Yu Tsun, Thaciane Alkmim Bibo, Fernando Luiz Affonso Fonseca, Glaucia Luciano da Veiga, Ana Carolina Macedo Gaiatto, Nicolle de Godoy Moreira E Costa, Joyce Regina Raimundo, Matheus Moreira Perez, Thaís Gascón, Fulvio Alexandre Scorza, Carla Alessandra Scorza, Helena Nader, Manoel João Batista Castello Girão, Beatriz da Costa Aguiar Alves, Edimar Cristiano Pereira","doi":"10.2174/1389200224666230109162132","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and aim: </strong>Vitamin D is the name given to a group of lipid-soluble steroidal substances of physiological importance in the body, especially in bone metabolism. The active form of vitamin D is believed to have immunomodulatory effects on immune system cells, especially T lymphocytes, as well as on the production and action of several cytokines and on the expression of potent antimicrobial peptides in epithelial cells that line the respiratory tract, playing an important role in protecting the lung from infections. The aim of this study was to assess vitamin D levels in patients with COVID-19 in healthcare service and to verify that these levels are adequate to protect the progression of this infection.</p><p><strong>Methods: </strong>The aim of this observational study was to evaluate the serum concentration of vitamin D in 300 patients suspected of being infected with COVID-19, treated at Basic Health Units (BHUs) and at the Hospital Complex in the municipality of São Bernardo do Campo.</p><p><strong>Results: </strong>294 patients were included, 195 (66%) of which tested positive for COVID-19 and 99 (34%) negative for COVID-19. Among the patients in the positive group, 163 patients were in the mild group (84%); 22 patients in the moderate group (11%); 8 patients in the severe group (4%), and 2 patients in the deceased group (1%).</p><p><strong>Conclusion: </strong>For the patients in this study, no association was observed for the protective factor of vitamin D against COVID-19 infection, and its role in controlling the clinical staging of the disease was not verified.</p>","PeriodicalId":10770,"journal":{"name":"Current drug metabolism","volume":"23 14","pages":"1124-1129"},"PeriodicalIF":2.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1389200224666230109162132","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and aim: Vitamin D is the name given to a group of lipid-soluble steroidal substances of physiological importance in the body, especially in bone metabolism. The active form of vitamin D is believed to have immunomodulatory effects on immune system cells, especially T lymphocytes, as well as on the production and action of several cytokines and on the expression of potent antimicrobial peptides in epithelial cells that line the respiratory tract, playing an important role in protecting the lung from infections. The aim of this study was to assess vitamin D levels in patients with COVID-19 in healthcare service and to verify that these levels are adequate to protect the progression of this infection.
Methods: The aim of this observational study was to evaluate the serum concentration of vitamin D in 300 patients suspected of being infected with COVID-19, treated at Basic Health Units (BHUs) and at the Hospital Complex in the municipality of São Bernardo do Campo.
Results: 294 patients were included, 195 (66%) of which tested positive for COVID-19 and 99 (34%) negative for COVID-19. Among the patients in the positive group, 163 patients were in the mild group (84%); 22 patients in the moderate group (11%); 8 patients in the severe group (4%), and 2 patients in the deceased group (1%).
Conclusion: For the patients in this study, no association was observed for the protective factor of vitamin D against COVID-19 infection, and its role in controlling the clinical staging of the disease was not verified.
简介和目的:维生素D是一组脂溶性甾体物质的名称,在体内具有重要的生理作用,特别是在骨代谢中。维生素D的活性形式被认为对免疫系统细胞,特别是T淋巴细胞,以及几种细胞因子的产生和作用以及呼吸道上皮细胞中强效抗菌肽的表达具有免疫调节作用,在保护肺部免受感染方面发挥重要作用。本研究的目的是评估医疗服务中COVID-19患者的维生素D水平,并验证这些水平是否足以保护这种感染的进展。方法:本观察性研究的目的是评估300名疑似感染COVID-19的患者的血清维生素D浓度,这些患者在 o Bernardo do Campo市的基本卫生单位(BHUs)和综合医院接受治疗。结果:纳入294例患者,其中COVID-19检测阳性195例(66%),阴性99例(34%)。阳性组中,轻度组163例(84%);中度组22例(11%);重症组8例(4%),死亡组2例(1%)。结论:在本研究患者中,未发现维生素D与COVID-19感染的保护因子相关,其在控制疾病临床分期中的作用尚未得到证实。
期刊介绍:
Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism.
More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.